# Tirzepatide Research — The 2024–2025 Clinical Trial Evidence > Tirzepatide clinical trial evidence: mechanism, SURPASS and SURMOUNT outcomes, and the 2024–2025 research record including SURMOUNT-5, SYNERGY-NASH, SURPASS-CVOT, and the safety meta-analyses — all cited. ## The short version Tirzepatide is a dual GIP/GLP-1 receptor agonist — a synthetic peptide that activates two gut-hormone receptors simultaneously, producing larger glucose and weight reductions than any single incretin agent has achieved in randomised trials. The SURPASS programme established its glycaemic efficacy in type 2 diabetes; the SURMOUNT programme established up to about 21% mean weight loss in adults with obesity. The 2024–2025 record extends the evidence base to MASH (a progressive fatty liver disease), heart failure with preserved ejection fraction, sleep apnea, and cardiovascular outcomes. Safety meta-analyses in this period also refined the signal around gallbladder disease, pancreatitis, lean-muscle loss, and the tolerability-efficacy trade-off versus older GLP-1 agents. ## Tirzepatide mechanism of action Tirzepatide activates two distinct incretin receptors: the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) and the GLP-1 receptor (glucagon-like peptide-1 receptor). Both are cell-surface G-protein-coupled receptors expressed on pancreatic beta cells and at multiple sites in the brain, gut, fat, and cardiovascular system. Coskun et al. (2018) established in in vitro assays that tirzepatide activates both receptors and confirmed glucose-dependent insulin secretion and body-weight reduction in mice beyond what a selective GLP-1 receptor agonist achieved [1]. Willard et al. (2020) characterised the imbalanced, biased pharmacology: tirzepatide engages the GIP receptor more fully than the GLP-1 receptor and favours cAMP (a key cell-signalling molecule) generation over beta-arrestin recruitment at the GLP-1 receptor. Beta-arrestin limits the insulin response to GLP-1 in primary islets but not to GIP or tirzepatide, suggesting the biased profile may enhance net insulin secretion [2]. Urva et al. (2020) characterised the PK/PD relationship from Phase 1 dose-ranging work, confirming the approximately five-day half-life that supports once-weekly subcutaneous dosing [28]. Campbell et al. (2023) synthesised the chemistry and physiology of dual GIP/GLP-1 agonism as an emerging drug class [13]. The downstream effects of dual agonism: glucose-dependent insulin secretion (amplified by both GIP and GLP-1); glucagon suppression (reduced liver glucose output); delayed gastric emptying (blunted post-meal glucose spikes); and central appetite reduction (sustained across weeks via hypothalamic and brainstem GLP-1 pathways). ## The SURPASS programme — glycaemic efficacy in type 2 diabetes SURPASS-2 (n=1,879, 40 weeks, open-label phase 3 RCT) — tirzepatide 5, 10, and 15 mg once weekly reduced HbA1c (glycated haemoglobin — average blood glucose over three months) by 2.01, 2.24, and 2.30 percentage points respectively versus 1.86 points with the comparator at 1 mg; all three tirzepatide doses were non-inferior and superior. Body-weight reductions with tirzepatide exceeded the comparator by -1.9, -3.6, and -5.5 kg at the three doses. Gastrointestinal adverse events were the most common, predominantly mild to moderate [3]. The SURPASS cardiovascular outcomes trial (SURPASS-CVOT, 2025) evaluated tirzepatide versus an established GLP-1 receptor agonist on major adverse cardiovascular events in adults with type 2 diabetes and high cardiovascular risk. This provides the long-term cardiovascular safety and efficacy comparator data for the class [35]. The 2026 meta-analysis by Qazi et al. synthesised nine trials versus dulaglutide and confirmed tirzepatide's greater glycaemic and weight efficacy, documenting the tolerability cost: discontinuation due to adverse events was approximately 32% higher with tirzepatide, driven by gastrointestinal effects. The efficacy benefit was consistent at HbA1c <7.0% in earlier-stage disease but smaller in long-standing disease with established cardiovascular disease [16]. ## The SURMOUNT programme — weight management SURMOUNT-1 (n=2,539, 72 weeks, double-blind phase 3 RCT) — in adults with obesity (BMI ≥30, or ≥27 with a weight-related complication) and without diabetes, once-weekly tirzepatide produced mean weight changes of -15.0% (5 mg), -19.5% (10 mg), and -20.9% (15 mg) versus -3.1% with placebo at week 72. Adverse events were predominantly gastrointestinal, occurring most frequently during the 20-week dose-escalation phase [4]. SURMOUNT-5 (n=751, 72 weeks, open-label, 2025) — the first large randomised head-to-head comparison of tirzepatide and semaglutide (a selective GLP-1 receptor agonist) for obesity in adults without diabetes. Least-squares mean weight change at week 72: -20.2% with tirzepatide versus -13.7% with the comparator (P<0.001). Tirzepatide achieved greater waist circumference reductions and higher rates of reaching 10%, 15%, 20%, and 25% weight-loss thresholds [5]. For the 2025 diabetes-prevention extension (SURMOUNT follow-up), Jastreboff et al. (2025) reported sustained weight reduction and reduced progression to type 2 diabetes over an extended follow-up [36]. A 2026 post-hoc analysis of SURMOUNT-1, -3, and -4 by Galindo et al. examined participants who were also taking weight-promoting medications (roughly 17–20% of each cohort) and found comparable percentage weight changes to the primary results — suggesting that tirzepatide's effect was maintained even in the presence of pharmacological headwinds [37]. ## 2024–2025 beyond-glycaemia evidence SYNERGY-NASH (published 2024) — in adults with MASH (metabolic dysfunction-associated steatohepatitis — a progressive fatty liver disease with inflammation and fibrosis) and moderate-to-severe fibrosis, tirzepatide produced significantly higher rates of MASH resolution without fibrosis worsening versus placebo in a randomised controlled trial [9]. SURMOUNT-OSA (published 2024) — in adults with moderate-to-severe obstructive sleep apnea (a condition where breathing repeatedly stops during sleep, graded by the apnea-hypopnea index — AHI — events per hour) and obesity, tirzepatide significantly reduced the AHI versus placebo, supporting the subsequent FDA approval for this indication [34]. SUMMIT (published 2025) — in adults with heart failure with preserved ejection fraction (HFpEF — a form of heart failure where the heart's pumping fraction remains normal) and obesity, tirzepatide significantly improved exercise capacity and reduced symptoms versus placebo [17]. Taken together, this 2024–2025 wave of readouts established tirzepatide as the first single agent to demonstrate benefit across type 2 diabetes, obesity, sleep apnea, MASH, and heart failure — an unusually broad clinical footprint driven by the compound's effects on adiposity and metabolic signalling. ## Safety evidence — the 2023–2025 meta-analytic record The corrected meta-analysis by Zeng et al. (2023) of nine randomised trials (9,871 participants) found no statistically significant increase in pancreatitis (relative risk 1.46, 95% CI 0.59–3.61), but a significantly increased risk of the composite of gallbladder or biliary disease (relative risk 1.97, 95% CI 1.14–3.42) [14]. The broader meta-analysis by Gong et al. (2025) of 12 trials reported a comparable biliary disease signal (relative risk 1.52) and cholelithiasis signal (relative risk 1.67) [18]. A class-level analysis confirmed gallbladder disorders are increased approximately 26% across GLP-1-based therapies [20]. Skeletal-muscle loss: Look et al. (2025) in a SURMOUNT-1 DXA substudy found approximately 25% of the weight lost was lean mass [24]. Batsis et al. (2026) in a systematic review put the median muscle-attributable share of weight loss near 28% across incretin trials, characterising the lean-mass loss as comparable to a decade or more of muscle ageing and recommending resistance exercise [25]. Locatelli et al. (2024) reviewed the role of resistance exercise in attenuating lean-mass loss [26]. Weight regain: SURMOUNT-4 (Aronne et al., 2024) demonstrated that participants switched to placebo after 36 weeks of tirzepatide regained weight while those continuing on tirzepatide kept losing, establishing the chronic-therapy framing [29]. Berg et al. (2025) documented cardiometabolic parameter deterioration alongside weight regain after discontinuation [30]. Horn et al. (2026) quantified cardiometabolic parameter changes with weight regain on tirzepatide withdrawal [31]. Hair loss: A 2025 Cureus review documented the pharmacovigilance data on GLP-1 receptor agonist-associated hair loss, confirming telogen effluvium as the proposed mechanism [32]. See [Tirzepatide references](/references) for the full citation list. --- A newsroom reading of the tirzepatide safety record — the 2024–2025 trials and meta-analyses set down and cited, with no clinic, no prescriber, and no verdict on any individual's risk.